MS: The Evolving Competitive Landscape, Future Challenges and Opportunities (2016)

This paper provides an overview of the treatment approaches for Multiple Sclerosis (MS) in 2016, together with an exploration of the current market dynamics and how they have evolved in recent years. It concludes with two case studies: 'Tecfidera: Still The Wonder Drug?' and 'Analysing Key Market Drivers'.

Unless stated otherwise, data and commentary are the result of analysis of Ipsos Global MS Therapy Monitor data (together with the market knowledge of Ipsos' MS experts). Running since 1997, the MS Therapy Monitor is an online multi-centre retrospective study of MS patients in the US and the EU5 (UK, France, Germany, Italy, Spain). Twice a year, 370 physicians (100 US & 270 EU5) are asked to report on 10 patients with the following quota: 7 RRMS; 2 SPMS; 1 CIS. Patient data elements collected include demographics, clinical status and diagnosis and treatment patterns. Physicians are also asked to complete a demographic form and perceptual questionnaire